Yabao Pharma inks second diabetes deal with Eli Lilly

21 October 2015

Chinese drugmaker Yabao Pharmaceutical (SSE: 600351) has entered into a second strategic collaboration for the treatment of diabetes with US pharma major Eli Lilly (NYSE: LLY) to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule.

Lilly's SGLT1 inhibitor program has completed a Phase I study in Singapore, in addition to extensive preclinical development. Last year (The Pharma Letter July 28, 2014), Lilly and Yabao also announced the co-development of Lilly's glucokinase activator (GKA), LY2608204.

Under the terms of the agreement, financial terms of which were not disclosed, Yabao receives the rights to develop and commercialize the SGLT1 compound in China, while Lilly retains rights in all other markets. The parties will collaborate to determine a strategic development plan for China, and Yabao will initially be responsible to perform and fund all development. Lilly retains future buy-in options for China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK